Dr. Marc de Perrot’s
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Distinguished by its potential for cure, Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a unique and challenging vascular disease characterized by the failure of acute pulmonary emboli to resolve, leading to chronic fibrous obstruction of pulmonary arteries. This persistent vascular remodeling results in progressive pulmonary hypertension and right heart failure. Our program is dedicated to advancing the understanding of CTEPH through rigorous research, from investigating genetic predispositions and molecular mechanisms to developing innovative diagnostic tools and refining treatment paradigms, ultimately aiming to transform patient prognoses.
Mesothelioma Cancer
Malignant Pleural Mesothelioma (MPM) is an aggressive and rare cancer strongly linked to asbestos exposure, characterized by a challenging prognosis and traditionally limited treatment options. Recent breakthroughs in immuno-oncology have revolutionized our approach to this formidable disease. While the tumor microenvironment of mesothelioma often presents an immunosuppressive landscape, current research is intensely focused on dissecting these intricate immune evasion mechanisms. Our work explores the dynamic interplay between tumor cells, stromal components, and immune infiltrates, with a particular emphasis on developing novel immunotherapeutic strategies. This includes refining immune checkpoint inhibitors, investigating adoptive cell therapies like CAR T-cells targeting mesothelioma-specific antigens, and identifying predictive biomarkers to stratify patient response. By unraveling the complex immunology of mesothelioma, we aim to transform therapeutic paradigms, improve patient survival, and foster long-term disease control.
Partners: Latner Labs
University of Toronto
University Health Network
